Venturing that the future of pharma will be genomic, drugmaker Eli Lilly said it plans to spend $700 million to establish the Lilly Institute for Genetic Medicine in Boston's Seaport District, part of the pharmaceutical giant's strategy to expand the development and production of gene-based therapies. The research hub will be located in a new 12-story building to be co-developed and operated by Alexandria Real Estate Equities where Eli Lilly agreed to lease approximately 334,000 square feet.
Eli Lilly Establishing $700 Million Boston Research Hub
Genomic R&D Facility To Accelerate New RNA and DNA-Based Medicines
RELATED ARTICLES
This news story is available exclusively to CoStar subscribers.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In
IN THIS ARTICLE
- Properties
- Innovation Point Phase II Land
15 Necco Ct, Boston, MA
- Lilly Seaport Innovation Center
15 Necco St, Boston, MA
- Athenaeum Center
215 First St, Cambridge, MA